Restech and Medstent Surgery Announce Strategic Partnership to Expand Distribution Throughout Central America

This collaboration marks a significant milestone in Restech’s mission to extend its medical solutions to healthcare professionals and patients across the globe.

HOUSTON, TX, UNITED STATES, September 1, 2023

Restech, provider of innovative reflux solutions, is proud to announce a renewed strategic partnership with Medstent Surgery throughout Central America. This collaboration marks a significant milestone in Restech’s mission to extend its medical solutions to healthcare professionals and patients across the globe.

As a cutting-edge medical device manufacturer, Restech is renowned for its commitment to enhancing patient care through innovative technologies. The partnership with Medstent Surgery aligns perfectly with this vision, enabling Restech to deliver its advanced medical devices to healthcare facilities throughout Central America. “We are thrilled to join forces with Medstent Surgery to bring our state-of-the-art medical devices to the healthcare landscape of Central America,” said Thomas Ball, PhD, Chief Commercial Officer of Restech. “Through this collaboration, we aim to make a positive impact on patient outcomes by providing healthcare professionals with the tools they need to deliver exceptional care.”

Restech’s range of reflux-oriented medical devices includes Stretta, which provides a safe, effective alternative to medication and anatomy altering surgery with an impressive history of clinical documentation. Stretta will now be easily accessible to hospitals, clinics, and healthcare providers across Central America. This partnership not only expands the market reach of Restech, but also allows medical practitioners in the region to leverage minimally invasive anti-reflux therapy.

“We are excited to partner with Restech and introduce their groundbreaking medical devices to our network of healthcare providers,” said Daniel Capuano, Director General of Medstent. “Their commitment to innovation and quality aligns perfectly with our values, and we look forward to a successful collaboration that enhances patient care in Central America.”

Through this collaboration, Restech and Medstent Surgery are poised to empower healthcare professionals in Central America with cutting-edge tools that can elevate the standard of Gastroesophageal Reflux. By combining Restech’s expertise in medical device manufacturing with Medstent’s extensive distribution network and market knowledge, the partnership is set to bring about transformative changes in the healthcare landscape of the region.  In addition to Medstent’s current territories of Mexico, Ecuador, Peru, and the Dominican Republic, Medstent will now represent Restech products in Panama, Nicaragua, Honduras, Belize, El Salvador, Guatemala, and Costa Rica.

For media inquiries and more information about Restech’s partnership with Medstent Surgery, please contact:
Arturo Quijano
Manager
Medstent Surgery
arturoq@medstentsurgery.com.mx
+52 5549992031

For United States:
Lauren Fisk
Marketing Manager
Restech
marketing@restech.com
+1 (858) 673-3700

About The Company
At Restech, we believe there is a better way to manage reflux: objective testing leading to better patient outcomes through custom treatment pathways. Our team accepted this challenge and launched the first real-time sensor that could function accurately in a non-liquid environment. Since then, we’ve obsessed over reflux, ensuring we understand the ins and outs of the disease state and industry. Although it is highly complex, we are passionate about bringing simple, effective reflux solutions to patients and clinicians around the world. Our rapid growth reflects our dedication and passion – developing and seeking out new products across the diagnostic and therapeutic continuum.

About MedStent Surgery
Medstent Surgery  is a company devoted to providing services in the Healthcare Sector. We have invested in cutting-edge technologies and innovative services, channeling our efforts towards successfully meeting the needs of our clients. Our founders, who have infused their knowledge, values, vision, and dreams into the company, established this enterprise with a strong commitment to enhancing health and quality of life.

About the Stretta Procedure
Stretta Therapy is a minimally invasive, endoscopic procedure that significantly reduces GERD symptoms, allowing a majority of patients to eliminate or significantly decrease use of PPIs. In an outpatient setting, Stretta is per­formed in less than 45 minutes, allowing patients to return to normal activities the fol­lowing day.

Boasting not only exceptional patient satisfaction, Stretta is the only widely studied minimally invasive treatment option for GERD – and has been proven safe and effective in more than 40 clinical studies and 35,000+ procedures. Durability studies indicate that many patients experience significant and lasting symptom relief for up to 15 years or beyond.  Restech acquired the Stretta procedure as part of its asset acquisition of Mederi Therapeutics in 2018.